Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
M2 Ingredients Inc. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action involves 1 distinct examiner and 1 distinct art unit. The prosecution is highly centralized, with all current activity occurring within a single technical group. This suggests a streamlined approach where the company is currently focused on a specific technical advancement rather than a broad array of filings.
BOECKELMAN, JACOB A is the busiest examiner, handling the 1 pending office action. Because there is only 1 distinct examiner, the company's current USPTO interactions are limited to a single individual. This concentration simplifies the management of the pending matter within the specified art unit. This centralized examination structure allows for a more predictable interaction with the patent office, as there are no competing examiner styles or differing art unit standards to navigate for the current pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516756 | Cordyceps Militaris Designated as Strain M2-105-04, Compositions, Methods of Making, Methods of Using and Methods for Treating Mammals | BOECKELMAN, JACOB A | 54d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516756 | Cordyceps Militaris Designated as Strain M2-105-04, Compositions, Methods of Making, Methods of Using and Methods for Treating Mammals | BOECKELMAN, JACOB A | 54d |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18516756 | Cordyceps Militaris Designated as Strain M2-105-04, Compositions, Methods of Making, Methods of Using and Methods for Treating Mammals | BOECKELMAN, JACOB A | 1655 | §101 | Final Rejection | 54d | Pending | Nov 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial